Adjuvant cheino and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827

S. E. Rivkin, S. Green, S. J. Altman, J. J. Costanzi, A. B. Cruz, C. Giarritta, W. R. Jewell, R. M. O'Bryan, C. K. Osborne

Research output: Contribution to journalArticlepeer-review

Abstract

On SWOG study 7827, 1725 (1597 eligible) T1-3 N1 MO breast cancer patients (pts) were randomized according to menopausal status and estrogen receptor status. Median follow-up time for 633 eligible (elig) pts last known to be aJive is 15 years (maximum 21). Estrogen receptor (ER) negative (-1 pis were randomized to combination chemotherapy with cytoxan. methotrexate, 5FLI. vincristine and prednisone (CMFVP) for one year vs two years (411 elig pts, 47% with 1-3 positive nodes, 46% premenopausal). Disease free (DF) and overall survival (S) comparisons remain non-significant (logrank p=.31, .67 respectively). ER positive (+1 premenopausal pts were randomized to CMFVP for one year vs CMFVP for one year plus oophorectomy (288 elig pis, 44% with I -3 positive nodes). Results remain non-significant for this part of the study as well as for both DPS and S (logrank p=.78, .67 respectively). ER + post-menopausal pts were randomized to tamoxifen (T) for one year vs CMFVP tor one year vs CMFVP plus T for one year (898 elig pts, 51 % with 1 -3 positive nodes). Four toxic deaths were noted on the chemotherapy arms on this part of the study (2 sepsis, 1 pneumonia, 1 pneumonitis). DPS and S differences remain non-significant (3 sample logrank p=. 19, .47 respectively). The most common causes of death in the 195 pts who died without a relapse reported were cardiovascular or other cancers.

Original languageEnglish (US)
Pages (from-to)249
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adjuvant cheino and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827'. Together they form a unique fingerprint.

Cite this